Venaxis Inc (NASDAQ:APPY)’s CE Marked APPY1 Test has shown positive top line results and it expects FDA approval based on the results. Venaxis announced positive top tine outcome from its fundamental U.S. study of the APPY1 Test, which is a multiple biomarker based assay which aims at identifying patients who are slightly vulnerable to appendicitis. Venaxis Inc (NASDAQ:APPY) shares after opening at $3.15 moved to $3.15 on last trade day and at the end of the day closed at $2.98. Company price to sales ratio in past twelve months was calculated as 1124.19 and price to cash ratio as 3.70. Venaxis Inc (NASDAQ:APPY) showed a positive weekly performance of 9.16%.
Liberator Medical Holdings, Inc. (nysemkt:LBMH) announced the financial results for its fiscal first quarter ended December 31, 2013. Liberator Medical Holdings Inc (NYSEMKT:LBMH) shares fell -7.58% in last trading session and ended the day on $3.90. LBMH return on equity ratio is recorded as 26.10% and its return on assets is 16.00%. Liberator Medical Holdings Inc (NYSEMKT:LBMH) yearly performance is 319.35%.
Marina Biotech, Inc. (OTCMKTS:MRNA) disclosed that it would be using its proprietary “RNAi, Antisense and microRNA Therapeutics Platform” in developing cures for some of the most rare diseases in the world. As per the new plan, it announced accelerated execution of its phase 1 clinical testing of target drug compound “Familial Adenomatous Polyposis”. Marina Biotech, Inc. (OTCMKTS:MRNA) shares moved down -7.79% in last trading session and was closed at $1.42 while trading in range of $1.37 – $1.59 – Marina Biotech, Inc. (OTCMKTS:MRNA) year to date (YTD) performance is 255.00%.
Nature’s Sunshine Products (NASDAQ:NATR) declared a quarterly dividend on Monday, March 17th,AnalystRatingsNetwork reports. Shareholders of record on Friday, March 28th will be given a dividend of 0.10 per share on Monday, April 7th. Nature’s Sunshine Prod (NASDAQ:NATR) weekly performance is -9.60%. On last trading day company shares ended up $14.03. Nature’s Sunshine Prod (NASDAQ:NATR) distance from 50-day simple moving average (SMA50) is -12.98%. Analysts mean target price for the company is $19.00.